Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Antithrombotic effect of Yamanouchi's YM-337

April 3, 1997

E-456, a minimum functional fragment of thrombomodulin from Asahi Chemical

April 3, 1997

New experimental data on Asahi Chemical's ART-123

April 3, 1997

Corvas begins phase Ia trial of rNAPc2

April 3, 1997

Menarini prepares thrombin inhibitors

April 3, 1997

New thrombin inhibitors from Novartis

April 3, 1997

VIMRx licenses factor IXa inhibitor from Columbia University

April 2, 1997

First generic warfarin product cleared by the FDA

April 1, 1997

Genzyme Transgenics receives further funding for development of transgenic ATIII

April 1, 1997

Terumo claims platelet aggregation/thromboxane synthase inhibitors

April 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.